Osborne Clarke advises LAVA Therapeutics on $83 million Series C financing.
Osborne Clarke in Amsterdam has advised LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, in the closing of an $83 million (€71 million) Series C financing to advance Novel Immuno-Oncology Programs.
The financing was co-led by new investors Novo Ventures and Sanofi Ventures, and included additional new investors Redmile Group, Ysios Capital and BB Pureos Bioventures. In addition, current investors Versant, Gilde Healthcare and MRL Ventures Fund, LLC participated significantly in the round.
The Osborne Clarke in Amsterdam team was led by Partner Herke van Hulst and included Senior Associate Geoffrey Beurskens, Partner Cars-Jan van Gool (Civil-Law Notary), Associate Arlette Vrolijk (Candidate Civil-Law Notary) and Associate Florien Sanders (Corporate M&A).
Osborne Clarke has a market-leading international venture capital practice and is widely recognized as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from Osborne Clarke in Amsterdam this year includes advising the investors on the EUR 32 million Series B financing round in VarmX, advising iOnctura on closing its EUR 20.1 Series A financing round and advising on Terumo’s acquisition of Quirem Medical.